The business of biologics: Aligning IP search and monitoring strategies with market trends

Biologics are more prominent in pharmaceutical pipelines, driven by advancements in personalized medicine. Despite this growth, the complexity and costs associated with developing biologics pose significant challenges, particularly with the looming threat of biosimilars and patent expirations.

Download the white paper to explore key insights into the business of biologics, including:

• The effectiveness of IP search and monitoring in identifying competitive threats early.
• The need for real-time visibility into patent landscapes to mitigate litigation risks.
• The development of sector-specific IP strategies, particularly in mRNA, gene therapies, and AI-driven biologics.
• Recommendations for executive teams to leverage IP intelligence to prioritize promising R&D initiatives.